198 related articles for article (PubMed ID: 28714013)
1. Glioblastoma entities express subtle differences in molecular composition and response to treatment.
Balça-Silva J; Matias D; Do Carmo A; Dubois LG; Gonçalves AC; Girão H; Canedo NHS; Correia AH; De Souza JM; Sarmento-Ribeiro AB; Lopes MC; Moura-Neto V
Oncol Rep; 2017 Sep; 38(3):1341-1352. PubMed ID: 28714013
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines.
Balça-Silva J; Matias D; do Carmo A; Girão H; Moura-Neto V; Sarmento-Ribeiro AB; Lopes MC
Biochim Biophys Acta; 2015 Apr; 1850(4):722-32. PubMed ID: 25554223
[TBL] [Abstract][Full Text] [Related]
3. PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma.
Liu Q; Xue Y; Chen Q; Chen H; Zhang X; Wang L; Han C; Que S; Lou M; Lan J
Oncol Rep; 2017 Nov; 38(5):2911-2918. PubMed ID: 29048655
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
Liu YJ; Ma YC; Zhang WJ; Yang ZZ; Liang DS; Wu ZF; Qi XR
Oncotarget; 2017 Jun; 8(26):42495-42509. PubMed ID: 28477008
[TBL] [Abstract][Full Text] [Related]
5. miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6.
Qian Z; Zhou S; Zhou Z; Yang X; Que S; Lan J; Qiu Y; Lin Y
Oncol Rep; 2017 Nov; 38(5):2941-2950. PubMed ID: 29048680
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
[TBL] [Abstract][Full Text] [Related]
8. BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomide.
Chen CM; Syu JP; Way TD; Huang LJ; Kuo SC; Lin CT; Lin CL
Int J Mol Med; 2015 Nov; 36(5):1244-52. PubMed ID: 26329365
[TBL] [Abstract][Full Text] [Related]
9. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
[TBL] [Abstract][Full Text] [Related]
10. Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Cheng Q; Ma X; Cao H; Chen Z; Wan X; Chen R; Peng R; Huang J; Jiang B
Mol Med Rep; 2017 Feb; 15(2):597-604. PubMed ID: 28035389
[TBL] [Abstract][Full Text] [Related]
11. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
12. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Atif F; Patel NR; Yousuf S; Stein DG
PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
[TBL] [Abstract][Full Text] [Related]
13. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
14. Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells.
Zhou RJ; Xu XY; Liu BX; Dai WZ; Cai MQ; Bai CF; Zhang XF; Wang LM; Lin L; Jia SZ; Wang WH
Int J Mol Med; 2015 Oct; 36(4):1159-64. PubMed ID: 26310668
[TBL] [Abstract][Full Text] [Related]
15. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.
Montaldi AP; Godoy PR; Sakamoto-Hojo ET
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():19-29. PubMed ID: 26520369
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance.
Motaln H; Koren A; Gruden K; Ramšak Ž; Schichor C; Lah TT
Oncotarget; 2015 Dec; 6(38):40998-1017. PubMed ID: 26517510
[TBL] [Abstract][Full Text] [Related]
17. miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
She X; Yu Z; Cui Y; Lei Q; Wang Z; Xu G; Xiang J; Wu M; Li G
Oncol Rep; 2014 Sep; 32(3):957-64. PubMed ID: 25017996
[TBL] [Abstract][Full Text] [Related]
18. Silencing of ZFP36L2 increases sensitivity to temozolomide through G2/M cell cycle arrest and BAX mediated apoptosis in GBM cells.
Che Mat MF; Mohamad Hanif EA; Abdul Murad NA; Ibrahim K; Harun R; Jamal R
Mol Biol Rep; 2021 Feb; 48(2):1493-1503. PubMed ID: 33590411
[TBL] [Abstract][Full Text] [Related]
19. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
[TBL] [Abstract][Full Text] [Related]
20. Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ.
Xu X; Wang Z; Liu N; Cheng Y; Jin W; Zhang P; Wang X; Yang H; Liu H; Zhang Y; Tu Y
Int J Oncol; 2018 Jul; 53(1):189-202. PubMed ID: 29749469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
